Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ)
CNY 9.35
(-0.32%)
CNY 9.35
(-0.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -37.24 Million | 152.55 Million | 255.42 Million | 63.79 Million | 67.24 Million | 57.93 Million |
| Net Income | -184.98 Million | 82.66 Million | 236.47 Million | 65.44 Million | 92.28 Million | 73.91 Million |
| Depreciation & Amortization | 33.47 Million | 30.36 Million | 24.16 Million | 5.51 Million | 163.03 Thousand | 63.73 Thousand |
| Deferred income taxes | -400.51 Thousand | -7.5 Million | -59.57 Thousand | -2.66 Million | 818.28 Thousand | -157.2 Thousand |
| Stock-based compensation | 7.89 Million | 26.16 Million | 2.78 Million | - | - | - |
| Change in working capital | -30.43 Million | -54.51 Million | -14.88 Million | -42.73 Million | -30.27 Million | -16.11 Million |
| Other non-cash items | 26.13 Million | 94.04 Million | 9.67 Million | 35.56 Million | 5.06 Million | 72.89 Thousand |
| Investing Cash Flow | -66.22 Million | -189.94 Million | -426.56 Million | -73.81 Million | -19.68 Million | -8.95 Million |
| Investments in PPE | -128.64 Million | -176.84 Million | -79.5 Million | -82.83 Million | -26.29 Million | -10.53 Million |
| Acquisitions | 4.95 Million | 541 Thousand | 0.18 | 43.08 Thousand | 26.29 Million | - |
| Investment purchases | -4.29 Million | -179.92 Million | -18.36 Million | -805 Million | -3.75 Million | - |
| Sales/Maturities of investments | 758.67 Thousand | 7.07 Million | 6.3 Million | 8.97 Million | 10.36 Million | 1.57 Million |
| Other Investing Activities | 61 Million | 159.21 Million | -335 Million | 805 Million | -26.29 Million | 0.14 |
| Financing Cash Flow | 333.12 Million | -53.84 Million | 140.63 Million | -46.22 Million | 209.27 Million | 34.1 Million |
| Debt repayment | -366.84 Million | -2.56 Million | -16.67 Million | -22 Million | - | - |
| Dividends payments | -8.49 Million | -99.81 Million | -18.03 Million | -45 Million | -7 Million | -28 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | -20.38 Million | -856.24 Thousand | - | - |
| Other Financing Activities | -20.77 Million | 49.36 Million | 179.06 Million | -1.22 Million | 216.27 Million | 62.1 Million |
| Accounts receivables | 24.71 Million | -29.25 Million | -38.91 Million | 5.93 Million | -39.12 Million | -23.14 Million |
| Accounts payables | -96.08 Million | 33.37 Million | 41.1 Million | -2.68 Million | 17.31 Million | 14.64 Million |
| Inventory | 41.33 Million | -51.13 Million | -17.01 Million | -43.31 Million | -9.27 Million | -7.45 Million |
| Other working capital | 7.89 Million | -7.5 Million | -59.57 Thousand | -2.66 Million | 818.28 Thousand | -8.66 Million |
| Cash at beginning of period | 247.18 Million | 339.23 Million | 374.23 Million | 440.76 Million | 183.12 Million | 99.48 Million |
| Cash at end of period | 481.74 Million | 247.18 Million | 339.23 Million | 374.23 Million | 440.76 Million | 183.12 Million |
| Capital Expenditure | -128.64 Million | -176.84 Million | -79.5 Million | -82.83 Million | -26.29 Million | -10.53 Million |
| Effect of forex changes on cash | 4.92 Million | -809 Thousand | -4.5 Million | -10.27 Million | 797.12 Thousand | 560.55 Thousand |
| Net cash flow / Change in cash | 234.56 Million | -92.04 Million | -35 Million | -66.52 Million | 257.63 Million | 83.63 Million |
| Free Cash Flow | -165.89 Million | -24.29 Million | 175.91 Million | -19.04 Million | 40.95 Million | 47.4 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 5.55 Million | -7.11 Million | -85.74 Million | -184.98 Million | -29.52 Million | -41.57 Million |
| Depreciation & Amortization | 7.1 Million | 7.1 Million | 33.47 Million | 33.47 Million | -15.06 Million | 11.61 Million |
| Deferred income taxes | - | - | - | -400.51 Thousand | 80.2 Million | -65.14 Million |
| Stock-based compensation | - | - | 7.89 Million | 7.89 Million | -7.88 Million | 7.88 Million |
| Change in working capital | - | - | 73.94 Million | -30.43 Million | -57.25 Million | 57.25 Million |
| Other non-cash items | 8.2 Million | 16.52 Million | -537.48 Thousand | 26.13 Million | 42.9 Million | 12.17 Million |
| Investing Cash Flow | -116.24 Million | -33.65 Million | -155.65 Million | -66.22 Million | 68.17 Million | -2.7 Million |
| Investments in PPE | -33.37 Million | -36 Million | -39.93 Million | -128.64 Million | -23.2 Million | -48.44 Million |
| Acquisitions | -74.13 Thousand | 2.17 Million | 4.28 Million | 4.95 Million | 646.45 Thousand | -86.73 Million |
| Investment purchases | -337.78 Million | - | -342 Million | -4.29 Million | -1.66 Million | -224.62 Million |
| Sales/Maturities of investments | 254.98 Million | 186.98 Thousand | 402.24 Million | 758.67 Thousand | 398.34 Thousand | 311.36 Million |
| Other Investing Activities | -116.85 Million | 357.11 Thousand | -120 Million | 61 Million | 92 Million | 45.73 Million |
| Financing Cash Flow | -8.58 Million | 44.12 Million | -32.41 Million | 333.12 Million | 340.36 Million | 29.38 Million |
| Debt repayment | -2.5 Million | -48.72 Million | -22.56 Million | -366.84 Million | -1.28 Million | -47.13 Million |
| Dividends payments | -1.23 Million | -1.21 Million | -8.49 Million | -8.49 Million | -1 Million | -10.12 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 2.14 Million | -4.59 Million | -8.61 Million | -20.77 Million | 342.65 Million | 86.65 Million |
| Accounts receivables | - | - | 24.71 Million | 24.71 Million | -12.73 Million | 12.73 Million |
| Accounts payables | - | - | - | -96.08 Million | - | - |
| Inventory | - | - | 41.33 Million | 41.33 Million | -32.28 Million | 32.28 Million |
| Other working capital | - | - | 7.89 Million | 7.89 Million | -12.23 Million | 12.23 Million |
| Cash at beginning of period | 500.35 Million | 648.55 Million | 648.55 Million | 247.18 Million | 229.09 Million | 211.79 Million |
| Cash at end of period | 386.55 Million | 500.35 Million | 481.74 Million | 481.74 Million | 648.55 Million | 229.09 Million |
| Capital Expenditure | -33.37 Million | -36 Million | -39.93 Million | -128.64 Million | -23.2 Million | -48.44 Million |
| Effect of forex changes on cash | 2.35 Million | -1.27 Million | 125.78 Thousand | 4.92 Million | -2.46 Million | 8.39 Million |
| Net cash flow / Change in cash | -113.79 Million | -148.2 Million | -166.8 Million | 234.56 Million | 419.45 Million | 17.29 Million |
| Free Cash Flow | -26.72 Million | -26.59 Million | -18.79 Million | -165.89 Million | -9.82 Million | -66.22 Million |
REGRF
QOMO
QOMOW
KGKC
000892
BACA